R1	Has_multiplier Arg1:T7 Arg2:T6	
*	OR T3 T4 T5
R2	Has_qualifier Arg1:T2 Arg2:T3	
*	OR T10 T11
R3	Has_temporal Arg1:T15 Arg2:T16	
T1	Post-eligibility 0 109	The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent
T2	Condition 140 161	GAA enzyme deficiency
T3	Qualifier 167 171	skin
T4	Qualifier 173 178	blood
T5	Qualifier 183 196	muscle tissue
T6	Multiplier 204 205	2
T7	Observation 216 234	GAA gene mutations
T9	Condition 256 269	Pompe disease
T10	Person 237 243	Infant
T11	Person 248 255	toddler
T12	Non-query-able 237 552	Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.
T13	Pregnancy_considerations 554 861	The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study
T14	Non-representable 864 919	For patients previously treated with alglucosidase alfa
T15	Drug 945 963	alglucosidase alfa
T16	Temporal 964 985	for at least 6 months
